EBITDA Margin % is calculated as EBITDA divided by its Revenue. Integrum AB's EBITDA for the
three
months ended in Apr. 2026 was kr-13.45 Mil. Integrum AB's Revenue for the
three
months ended in Apr. 2026 was kr25.06 Mil. Therefore, Integrum AB's EBITDA margin for the quarter that ended in Apr. 2026 was -53.67%.
Integrum AB (OSTO:INTEG B) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Integrum AB EBITDA Margin % Related Terms
Integrum AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Integrum AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:INTEG B vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Integrum AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Integrum AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integrum AB (OSTO:INTEG B) has a EBITDA Margin % of -53.67% as of Apr. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integrum AB and its competitors. According to the industry distribution chart, Integrum AB ranks #629 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 77.1%.
Is Integrum AB's EBITDA Margin % too high?
Integrum AB's current EBITDA Margin % is -53.67%. Based on the distribution chart, Integrum AB ranks #629 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integrum AB has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #629 out of 816 companies for EBITDA Margin %. This places Integrum AB in the lower half of its industry. The industry median EBITDA Margin % is 7.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Integrum AB and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current EBITDA Margin % is -53.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (OSTO:INTEG B) is currently considered Possible Value Trap. The stock's GF Value™ is kr17.76, compared to a current price of kr8.40 — trading 52.7% below its estimated fair value. The current EBITDA Margin % is -53.67%. Integrum AB's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Integrum AB (OSTO:INTEG B), the current EBITDA Margin % is -53.67% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (OSTO:INTEG B) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of kr8.40 is trading 52.7% below its estimated GF Value™ of kr17.76.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for OSTO:INTEG B:
EBITDA Margin %: -53.67%
GF Value™: kr17.76 vs. price of kr8.40 (52.7% below fair value)
No single metric tells the full story. See the OSTO:INTEG B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
57GF Score
Get the complete analysis for OSTO:INTEG B
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:INTEG B has been successfully added to your 
